CGM devices should be considered for patients with T1D and T2D who are on intensive insulin therapy to improve HbA1c levels and reduce hypoglycemia (Grade B), early reports suggest that even patients not taking insulin may benefit from CGM (Grade D). This evidence concerns the gene INS and Hypoglycemia.